Login to your account

Username *
Password *
Remember Me

Blog With Right Sidebar

Prospective Study of the Incidence of Contrast-induced Nephropathy Among Patients Evaluated for Pulmonary Embolism by Contrast-enhanced Computed Tomography.

Objectives:  Contrast-enhanced computed tomography (CECT) of the pulmonary arteries (CTPA) has become the mainstay to evaluate patients with suspected pulmonary embolism (PE) and is one of the most common CECT imaging studies performed in the emergency department (ED). While contrast-induced nephropathy (CIN) is a known complication, this risk is not well defined in the ED or other ambulatory setting. The aim of this study was to define the risk of CIN following CTPA.

Methods: The authors enrolled and followed a prospective, consecutive cohort (June 2007 through January 2009) of patients who received intravenous (IV) contrast for CTPA in the ED of a large, academic tertiary care center. Study outcomes included 1) CIN defined as an increase in serum creatinine (sCr) of 0.5ƒmg/dL or 25%, 2 to 7ƒdays following contrast administration; and 2) severe renal failure defined as an increase in sCr to 3.0ƒmg/dL or the need for dialysis within 45days and/or renal failure as a contributing cause of death at 45ƒdays, determined by the consensus of three independent physicians.

Results: A total of 174 patients underwent CTPA, which demonstrated acute PE in 12 (7%, 95% confidence interval [CI]ƒ=ƒ3% to 12%). Twenty-five patients developed CIN (14%, 95% CIƒ=ƒ10% to 20%) including one with acute PE. The development of CIN after CTPA significantly increased the risk of the composite outcome of severe renal failure or death from renal failure within 45ƒdays (relative riskƒ=ƒ36, 95% CIƒ=ƒ3 to 384). No severe adverse outcomes were directly attributable to complications of venous thromboembolism (VTE) or its treatment.

Conclusions:‚ In this population, CIN was at least as common as the diagnosis of PE after CTPA; the development of CIN was associated with an increased risk of severe renal failure and death within the subsequent 45ƒdays. Clinicians should consider the risk of CIN associated with CTPA and discuss this risk with patients.

Related Articles
Acad Emerg Med. 2012 Jun;19(6):618-25
Authors: Mitchell AM, Jones AE, Tumlin JA, Kline JA
Read Full Article

Search